Atrium Therapeutics, Inc.(RNA)
$7.51+0.01 (+0.13%)
RNA
Atrium Therapeutics, Inc. financials statements
$7.51
At close:+0.01 (+0.13%)
Want to see RNA full AI Analyst Report?
Atrium Therapeutics, Inc. (RNA) Income Statement
25 Followers
Atrium Therapeutics, Inc. Income Statement
Last quarter (Q3 2026), Atrium Therapeutics, Inc.'s total revenue was $15.32M, an increase of 22.81% from the same quarter last year. In Q3, Atrium Therapeutics, Inc.'s net income was $-4.27M. See Atrium Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 18.62M | $ 10.90M | $ 9.56M | $ 9.22M | $ 9.33M | |
| $ 18.62M | $ 10.90M | $ 7.46M | $ 7.84M | $ -91.86M | |
| $ 95.43M | $ 389.83M | $ 243.06M | $ 186.75M | $ 26.20M | |
| Depreciation and Amortization | $ 323.00K | $ 2.78M | $ 2.10M | $ 1.39M | $ 639.00K |
| $ -76.50M | $ -376.16M | $ -233.50M | $ -177.53M | $ -117.41M | |
| $ -76.81M | $ -378.94M | $ -235.60M | $ -178.91M | $ -118.05M | |
| $ -12.00K | $ 56.63M | $ 23.38M | $ 4.92M | $ 42.00K | |
| $ -76.83M | $ -322.30M | $ -212.22M | $ -174.00M | $ -118.01M | |
| $ -76.68M | $ -322.30M | $ -212.22M | $ -174.00M | $ -118.01M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.48 | $ -2.89 | $ -2.91 | $ -3.34 | $ -2.85 |
| Diluted EPS | $ -4.48 | $ -2.89 | $ -2.91 | $ -3.34 | $ -2.85 |
| Weighted Average Shares Outstanding | 17.11M | 111.58M | 73.01M | 52.16M | 41.43M |
| Weighted Average Shares Outstanding (Diluted) | 17.11M | 111.58M | 73.01M | 52.16M | 41.43M |
Currency in USD

